Atuzabrutinib

• CAT Number: I022641
• CAS Number: 1581714-49-9
• Molecular Formula: C30H30FN7O2
• Molecular Weight: 539.60
• Purity: ≥95%
• Synonyms: (E)-2-[(3R)-3-[4-amino-3-(2-fluoro-4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile
• InChI: InChI=1S/C30H30FN7O2/c1-30(2,3)15-19(16-32)29(39)37-13-7-8-20(17-37)38-28-25(27(33)34-18-35-28)26(36-38)23-12-11-22(14-24(23)31)40-21-9-5-4-6-10-21/h4-6,9-12,14-15,18,20H,7-8,13,17H2,1-3H3,(H2,33,34,35)/b19-15+/t20-/m1/s1
• InChIKey: KZMQPYCXSAGLTB-ZWUNQBBJSA-N
• SMILES: CC(C)(C)C=C(C#N)C(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=C(C=C(C=C4)OC5=CC=CC=C5)F)N

Atuzabrutinib (Cat No.: I022641) is an investigational, selective Bruton’s tyrosine kinase (BTK) inhibitor being developed for the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. By selectively inhibiting BTK, a key component of the B-cell receptor signaling pathway, atuzabrutinib disrupts malignant B-cell proliferation and survival. Its design aims to improve efficacy while reducing off-target effects and associated toxicities seen with earlier BTK inhibitors. Atuzabrutinib is currently undergoing clinical evaluation for its safety and therapeutic potential in hematologic cancers.

Reference

[1]. Herter JM, et al. PRN473, an inhibitor of Bruton’s tyrosine kinase, inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling. Br J Pharmacol. 2018;175(3):429-439.
[Content Brief]